This script search US Code. View Rule
Menu Item - Home
Menu Item - Agenda Main page
Menu Item - Historical Agenda
Menu Item - Historical Agenda
Menu Item - Agenda Search
Menu Item - EO Dashboard
Menu Item - Reg Review
Menu Item - EO Agency lists
Menu Item - EO Search
Menu Item - EO Historical Reports
Menu Item - Review Counts
Menu Item - OIRA Letters
Menu Item - EOM 12866 Search
Menu Item - EO XML Reports
Menu Item - ICR Dashboard page
Menu Item - ICR Main page
Menu Item - ICR Search
Menu Item - ICR XML Reports
Menu Item - FAQ
Menu Item - Additional Resources
Menu Item - Contact Us
Search: Agenda Reg Review ICR
       Search

View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

HHS/NIH RIN: 0925-AA55 Publication ID: Fall 2011 
Title: Expanded Registration and Results Reporting at ClinicalTrials.gov 
Abstract: The National Institutes of Health (NIH) proposes to issue new regulations that will prescribe procedures for registering and reporting the results, including adverse events, of clinical trials in ClinicalTrials.gov, in accordance with section 801 of the Food and Drug Administration Amendments Act of 2007, (FDAAA, PL. 110-85). As previously announced, the agency intends to proceed with a single rulemaking to implement the expanded registry, results reporting, and adverse event information reporting requirements of the statute. The rulemaking will also consider topics that the statute requires to be addressed in regulations intended [to provide more complete results information and to enhance patient access to and understanding of the results of clinical trials] [as codified in 42 U.S.C. 282(j)(3)(D)], including whether results information should be required to be submitted for applicable clinical trials of drugs, biological products, or devices that have not been approved, licensed, or cleared by the Food and Drug Administration, and whether narrative summaries of clinical trials and their results can be included in the data bank without being misleading or promotional. These topics were the subject of discussion at the public meeting organized by NIH in April 2009, and of written public comments. The regulations will identify the trials that are subject to the registration and results reporting requirements (including adverse event reporting); the specific information and format of the information that must be submitted to ClinicalTrials.gov; deadlines for registering and reporting results; procedures for extending the deadlines or waiving the submission requirements; and procedures for agency review and public posting of submitted information. 
Agency: Department of Health and Human Services(HHS)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Proposed Rule Stage 
Major: No  Unfunded Mandates: No 
CFR Citation: 42 CFR 3 
Legal Authority: 42 USC282(i); 42 USC 282(j); 5 USC 301; 42 USC 286(a); 42 USC 241(a); 42 USC 216(b) 
Legal Deadline:
Action Source Description Date
Final  Statutory    09/27/2010 
Timetable:
Action Date FR Cite
NPRM  04/00/2012   
Regulatory Flexibility Analysis Required: Undetermined  Government Levels Affected: None 
Small Entities Affected: Businesses  Federalism: No 
Included in the Regulatory Plan: No 
RIN Data Printed in the FR: No 
Agency Contact:
Jerry Moore
NIH Regulations Officer
Department of Health and Human Services
National Institutes of Health
Room 601 MSC 7669, 6011 Executive Boulevard,
Rockville, MD 20852
Phone:301 496-4606
Fax:301 402-0169
Email: jm40z@nih.gov

 
About Us   Vertical Spacer Spacer Related Resources   Vertical Spacer Spacer Disclosure   Vertical Spacer Spacer Accessibility   Vertical Spacer Spacer Privacy Policy   Vertical Spacer Spacer Contact Us